2019
LBA21 KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)
Cortés J, Lipatov O, Im S, Gonçalves A, Lee K, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Zambelli S, Harbeck N, André F, Dent R, Zhou X, Karantza V, Mejia J, Winer E. LBA21 KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC). Annals Of Oncology 2019, 30: v859-v860. DOI: 10.1093/annonc/mdz394.010.Peer-Reviewed Original ResearchMetastatic triple-negative breast cancerCombined positive scoreSubsidiary of MerckGerman Study GroupDohme Corp.Merck SharpSeattle GeneticsGrade 3Study groupOpen-label phase III studyPD-L1 combined positive scoreEnd pointTriple-negative breast cancerDaiichi SankyoF. Hoffman-La RochePrior systemic treatmentPrimary end pointSecondary end pointsSingle-agent chemotherapyPhase III studyHigh-grade toxicityNegative breast cancerPD-L1 enrichmentTreatment effectsBristol-Myers Squibb
1990
Improved survival in advanced Hodgkin's disease with the use of combined modality therapy
Brizel D, Winer E, Prosnitz L, Scott J, Crawford J, Moore J, Gockerman J. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. International Journal Of Radiation Oncology • Biology • Physics 1990, 19: 535-542. PMID: 2211201, DOI: 10.1016/0360-3016(90)90478-3.Peer-Reviewed Original ResearchConceptsSoutheastern Cancer Study GroupAdvanced Hodgkin's diseaseModality therapyTherapy patientsHodgkin's diseaseSoutheastern Cancer Study Group trialTen-year actuarial survivalInduction combination chemotherapyCancer Study GroupActuarial freedomActuarial survivalConsolidation radiotherapyAlone patientsPartial responseCombination chemotherapyInitial diagnosisChemotherapy patientsAcute leukemiaStudy groupGroup trialsChemotherapyPatientsMulti-variate analysisTherapyRelapse